Drugs against ageing

5 Alarm Bio develops small-molecule therapeutics targeting an unexplored aging mechanism to delay or prevent age-related diseases.

712 North develops personalized mitochondrial medicines for age-related diseases.

ADvantage Therapeutics develops novel therapeutics for neurodegenerative conditions, with a major focus on Alzheimer’s disease.

Clinical-stage biopharmaceutical company developing selective small molecules for rare genetic and age-related diseases.

AKL Therapeutics develops APPA, an investigational oral therapy for osteoarthritis and other inflammatory diseases of ageing.

Amplifier Therapeutics develops AMPK activators to address metabolic disease and aging-related chronic diseases.

Antoxis conducted research and experimental development in biotechnology.

Atropos develops senescence-targeting drugs for aging-related diseases, cancer, and healthspan.

Biophytis develops transformative therapies impacting longevity, with BIO101 programs in sarcopenia and obesity.

Bolden Therapeutics develops first-in-class therapeutics to increase neurogenesis and improve outcomes in neurological disease.

Clinical-stage drug development company developing therapeutics targeting metabolic pathways that decline with age.

Cognition Therapeutics develops therapies for age-related neurodegenerative diseases including dementia with Lewy bodies and Alzheimer’s disease.

Clinical-stage biotechnology company developing multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.

Epirium Bio develops oral small-molecule therapies targeting PGE-2 signaling for neuromuscular, inflammatory, and fibrotic diseases.

Etheros develops small molecule enzyme mimetics for neuroprotection and healthspan.

Fission Pharma is developing DRP1-FIS1 protein-protein interaction inhibitors for chronic inflammation, mitochondrial dysfunction, and age-related degenerative diseases.

Galilei Biosciences develops small-molecule SIRT6 activators for neuroprotection in glaucoma and other age-related diseases.

Hayflick Therapeutics develops localized, micro-dose rapamycin therapies targeting mTOR for cellular aging interventions in skin.

Clinical-stage biopharmaceutical company developing fusion immunotherapies for autoimmune diseases, cancer and senescence-associated dysplasia.

Clinical-stage biotech developing stem cell-derived secretome biologics targeting age-related muscle and metabolic disease.

Istesso develops first-in-class oral regenerative medicines focused on restoring the body’s natural capacity to repair tissue.

Jocasta develops Klotho-based therapeutics for cognitive vitality and age-related cognitive impairment.

A clinical-stage drug platform company focused on treating neuroinflammation.

Juvenescence develops innovative medicines targeting core aging mechanisms to extend healthy lifespan and prevent age-related diseases.

LinkGevity develops AI-driven longevity therapeutics, including first-in-class Anti-Necrotic necrosis inhibitors for kidney disease and other applications.

Loyal develops longevity drugs for dogs that target age-associated disease and disability.

MetroBiotech develops proprietary NAD+ precursors to enhance human healthspan and treat age-related diseases.

Mirscience Therapeutics develops personalized microRNA therapies for longevity-associated diseases and challenging therapeutic targets.

MitoChem Therapeutics develops small molecules targeting mitochondrial dysfunction-driven loss of cellular metabolism in neurodegenerative disease.

Mitoconix Bio develops disease-modifying therapeutics for neurodegenerative diseases by improving mitochondrial health.

Mitotech develops orally bioavailable small molecules to protect mitochondria from oxidative stress and enhance energy expenditure.

Mogling Bio develops pharmacological therapies targeting Cdc42 overactivation to rejuvenate aged and exhausted cells, especially stem cells.

Muna Therapeutics develops therapies to slow or stop neurodegenerative diseases including Alzheimer’s and Parkinson’s.

Napa Therapeutics develops small molecule drugs against a novel aging-related target linked to NAD metabolism.

Neuro-Bio develops diagnostic and therapeutic strategies for Alzheimer's disease based on the toxic T14 peptide mechanism.

NRG Therapeutics develops disease-modifying medicines for neurodegenerative disorders by targeting mitochondrial function.

NuSirt Sciences combines established pharmaceuticals and natural products to activate the sirtuin pathway for cardiometabolic diseases of aging and overnutrition.

Olatec develops safe oral NLRP3 antagonist therapeutics for acute and chronic inflammatory diseases.

Pelage develops regenerative medicines for hair loss grounded in stem cell biology.

PharmatrophiX develops small-molecule disease-modifying therapies for neurodegenerative diseases.

Pretzel develops first-in-class medicines targeting mitochondrial biology and cellular energetics for rare, neurodegenerative, metabolic, and other diseases.

Refoxy develops next-generation medicines targeting FOXO3 to treat age-related diseases and extend healthy lifespan.

Clinical-stage biopharmaceutical company developing medicines targeting the biology of aging to prevent or treat aging-related diseases.

Retrotope develops proprietary therapeutics designed to treat degenerative disease by down-regulating lipid peroxidation.

Scripta Therapeutics modulates transcription factor activity using AI/ML-driven drug discovery to develop disease-modifying therapeutics.

Senisca develops RNA senotherapeutics to reverse cellular senescence and treat age-related disease.

Sentcell develops first-in-class human rejuvenating therapies targeting the sMAC pathway in ageing T cells.

A therapeutics company developing degradation-resistant Hox family biologics.

Clinical-stage biopharma developing MYMD-1 and Supera-CBD for autoimmune, inflammatory, aging-related, pain, anxiety and seizure indications.

TOR Therapeutics develops an oral fixed-dose combination of mTORC1 inhibitors for Alzheimer's disease and other mTORC1-driven disorders.

Tornado Therapeutics is developing safer, more effective rapalogs to treat disease and extend healthy lifespan.

TriviumVet develops animal health therapeutics for serious diseases in cats and dogs.

Vasa develops therapeutics targeting cardiovascular aging, neuromuscular disease, and age-related disorders.

X-tosis develops mitochondrial therapeutics to prevent neuronal loss in neurodegenerative diseases.

YOXLO builds science-based tools, products and research programs to help people understand and preserve functional reserve as they age.

Zoe Biosciences is developing best-in-class therapies to treat cardiometabolic disease.

A NEW DIMENSION appears to be Aayam Therapeutics’ mitochondria-focused longevity effort: a drug-discovery and development project built around an undisclosed "LADR 4" platform and framed as delivering affordable, accessible therapeutics. The strongest external signal is selection on 2025-05-12 as an XPRIZE Healthspan Top 40 Milestone 1 awardee, but the public technical record in this evidence set is thin and mostly promotional; there is no disclosed mechanism, named candidate, preclinical dataset, or clinical outcome here.

Alpha Rejuvenation appears to be a California-focused men’s health and wellness clinic marketing peptide therapies, testosterone replacement, erectile-dysfunction treatment, pelvic-floor therapy, NAD+, and semaglutide-based weight loss rather than a clearly documented R&D program. The strongest evidence is self-authored promotional clinic content describing services, testimonials, and operational constraints; there is little independent evidence here for efficacy, safety, or a distinctive longevity intervention, and the project’s canonical URL is undermined by a likely source-matching error involving an unrelated Japanese environmental site.

Aptah Bio is a U.S.-based startup developing RNA therapeutics, centered on a U1 snRNP-modulating platform it calls RNA WiCo/RNA rejuvenation, for neurodegeneration, cancer, and other age-related diseases. The strongest project-specific evidence is still preclinical: a 2024 Scientific Reports paper reports biomarker and electrophysiology improvements for APT20TTMG in Alzheimer’s iPSC-derived neurons and SAMP8 mice, while commercial databases and company posts show a broader preclinical pipeline and claimed non-dilutive funding. The core promise is unusually broad RNA-level correction across multiple proteins and pathways, but most high-claim statements come from company-controlled or promotional sources, and there is no clinical evidence yet.

Beijing Joekai Biotechnology appears to be a Beijing-based small-molecule neurodegeneration company centered on Alzheimer’s disease. The strongest direct evidence is company-assigned patenting around synthetic compounds for Alzheimer’s treatment, recent conference coverage of a Rac1 inhibitor candidate called 50561 with preclinical Alzheimer’s results, and trial listings showing a completed randomized Phase IIa study of 50561 in 68 patients with mild to moderate Alzheimer’s disease in China. The main caution is that most evidence is patent, directory, or conference metadata rather than peer-reviewed efficacy data, and no human results are provided in the supplied evidence.

Beiwe appears to be an early therapeutic project centered on selective mTORC1 inhibition for longevity and cancer, with the core claim that it can preserve rapamycin-like benefits while avoiding mTORC2-related toxicity; however, the evidence here is mostly undated self-published website copy with no linked primary datasets, study details, patent record tied to the company, or disclosed clinical results.

BioArmor appears to be an early-stage, student-led longevity concept from the QuestX Incubator in Kuala Lumpur that reached XPRIZE Healthspan semifinalist status, but the public evidence does not disclose a validated therapeutic program. The clearest project-specific description is a June 25, 2025 Facebook post describing a speculative "BioArmor X" stack spanning a supplement/drink, future injection/serum, and topical gel/patch for regeneration, immunity, and age reversal, while also admitting that full age reversal, nanobots, and more extreme claims remain future-facing rather than demonstrated.

Cura Therapeutics appears to be a small, women-led biotech developing multifunctional fusion-protein therapeutics for metastatic cancer and age-related diseases, with recurring claims around multimodal immune activation plus anti-fibrotic and anti-senescence effects. The strongest evidence is not clinical; it is a mix of company materials, startup-program listings, platform databases with sparse detail, founder-linked patents, and older academic fusokine literature tied to Claudia Penafuerte Diaz and Jacques Galipeau. That supports a real translational program and relevant team lineage, but not validated efficacy, safety, or durable clinical progress.

Klotho Longevity is a U.S. commercialization effort centered on Klotho-linked anti-aging products and procedures, led by Dr. Gail Humble and closely tied to the Klotho Skin brand. The evidence shows active branding, clinic offerings, and patent activity around Klotho production and skin-care use, but project-specific validation is thin: the strongest direct human evidence is a small 2025 pilot study of a topical Klotho serum for photoaging in 16 women, not a systemic longevity intervention.

Lono Jaeyak appears to be an anti-senescence composition program known only from a pending European patent application claiming formulations for rejuvenating senescent cells or delaying/preventing cellular aging. The available evidence supports IP activity and broad product positioning across possible nutraceutical, feed, and medicinal uses, but it does not show validated mechanism, preclinical efficacy, safety, or human data.

Nishimura Lab appears, on the evidence provided, to be an EADERM-linked regenerative dermatology effort built around hair follicle and epidermal stem-cell biology, especially aging- and injury-related mechanisms involving COL17A1 and stem-cell motility. The strongest project-specific signals are company pages describing stem-cell-based drug discovery and alopecia therapeutic development, plus Emi K. Nishimura-linked academic work on hair thinning, hair follicle aging, and skin regeneration. However, much of the translational evidence is still indirect: company pages are promotional, patents are claims rather than validation, and the provided paper excerpts are mostly title/metadata level rather than full results.

NYC-Vita is a Mount Sinai-led, New York City pilot longevity trial that appears to combine home-based exercise, daily spermidine, and low-dose rapamycin or lamivudine in adults roughly 65-80, with the stated goal of improving immune function, muscle strength, cognition, and overall healthspan. The project has clear institutional backing and XPRIZE Healthspan semifinalist status, but the evidence here is mostly press, partner-content, and social posts plus secondary media coverage; there are no published trial results, and even basic questions about efficacy, mechanism, attribution, and safety remain unresolved.

RIGHT Trial appears to be a University of Pittsburgh-led Phase 2, 24-week, placebo-controlled trial testing subcutaneous clazakizumab, an IL-6 blocker, in older adults with frailty and mobility limitation. The central bet is that lowering inflammatory signaling can improve practical function such as walking speed, but the provided evidence is mostly participant-facing trial description and design context rather than published efficacy results, so credibility rests more on a plausible mechanism and formal trial structure than on demonstrated benefit so far.

Team GlyNAC appears to be a Baylor College of Medicine-associated translational longevity project built around GlyNAC, a glycine plus N-acetylcysteine supplementation strategy intended to raise glutathione and improve mitochondrial and oxidative-stress-related aging defects. The evidence base is suggestive but still limited: there are pilot and randomized older-adult studies reporting improvements in biomarkers and some functional measures, plus mouse studies reporting lifespan, cognition, and cardiac effects, but much of the accessible material is Baylor news coverage, small early-stage studies, or preclinical work, with human durability, safety, and hard clinical outcomes still unresolved.

Team Twilight is a U.S. biotech startup developing active immunotherapies against pathological proteins, especially HERV-K-linked targets in ALS, with broader stated ambitions in Alzheimer’s, Parkinson’s, and chronic pain. The strongest direct evidence is the company’s own claims about its Ambifect Fc-fusion platform, leadership, and intended indications; the stronger independent evidence sits one layer back, supporting HERV-K as an ALS-related biomarker and mechanistic target class rather than validating Team Twilight’s product. The core uncertainty is that no clinical efficacy data for Team Twilight’s program are provided here.

The Brigham-Boston XPRIZE Healthspan Team is a Mass General Brigham and Harvard-linked effort that became a Top 40 semifinalist in the seven-year, $101M XPRIZE Healthspan competition and received $250,000 in Milestone 1 funding in 2025. Led by Shalender Bhasin and JoAnn Manson, the team is running a preliminary program around an unnamed “promising new therapeutic” intended to extend healthspan and delay major age-related conditions. The evidence shows strong institutional leadership and real competition progress, but it is still an institutional announcement about pilot-stage work, not peer-reviewed efficacy evidence or a demonstrated clinical success.

TIME TRAVELER AND NUREKI presents as a University of Tokyo-linked startup pursuing healthy-aging products and therapeutics, especially plant-cell-derived exosomes and molecules said to inhibit aging-linked genes, with stated interests in cancer, frailty/sarcopenia, cachexia, supplements, and cosmetics. The strongest concrete evidence here is corporate self-description plus commercialization signals around a parsley-derived supplement (`exofull FUJI`) and broad patent-field context on plant-derived exosomes and muscle-loss indications. There is no peer-reviewed efficacy, clinical, or regulatory evidence in the provided record, so the project currently looks more like an early translational startup with ambitious claims than a validated longevity program.

YOXLO is a Dutch longevity startup building a proprietary healthspan intervention, Youniqor, around a centenarian-inspired thesis that mitochondrial function, cellular resilience, and inflammatory control, especially NLRP3-linked immune signaling, can be modulated to preserve strength, cognition, independence, and immune function with age. The evidence supports a real company, named team, patents, a 2024 review by founder Stef Verlinden, and 2025 XPRIZE Healthspan semifinalist status, but not convincing efficacy: the intervention evidence here is mostly company claims, review-level argument, and patent positioning rather than disclosed clinical outcomes.